Simon-Kucher whitepaper examines the impact of drug pricing uncertainty on early-stage biotech valuations

As Most Favoured Nation (MFN) drug pricing policies increase uncertainty around future drug revenues, early-stage biotech companies face greater scrutiny from investors and potential partners.

The paper from Simon-Kucher examines the implications for biotech valuations, investment decisions and commercial strategies, highlighting how companies can address pricing risks, demonstrate asset value and strengthen their position in funding and partnering discussions.

The paper also outlines practical considerations for managing pricing uncertainty and supporting long-term commercial potential.

Read the whitepaper: skp.link/bgga